… ) trial showed the superiority of adjuvant gefitinib over … open-label, phase II, randomized
controlled trial of erlotinib versus GC … All patients were randomly assigned 1:1 to receive erlotinib …

… randomized, double-blind, placebo-controlled study was … Versus Taxotere) trial, a noninferiority
trial of gefitinib versus docetaxel … to predict improved survival with gefitinib. EGFR protein …

… First, another EGFR TK inhibitor (erlotinib, OSI774) which demonstrated promising activity
in phase I studies comparable with gefitinib. A randomized placebo-controlled trial of erlotinib …

… Another EGFR tyrosine kinase inhibitor, gefitinib, has demonstrated noninferiority
compared with docetaxel in a randomized controlled trial as a second-line therapy ( 26 ), but a …

… On the basis of preclinical and early clinical studies, we … erlotinib compared with patients
treated with erlotinib or … prospective, multicenter, randomized controlled design in which …

… and laboratory, that must be considered in the design of clinical trials and in evaluating our
patients for treatment outside a protocol. The positive factor, though, is that an addition has …

… data of clinical trials with EGFR TKIs, especially erlotinib, for … Erlotinib or gefitinib versus
placebo in second- and third-line … between studies showed that gefitinib and erlotinib produced …

… needs to be demonstrated in clinical trials. Unfortunately, no … Also, before additional clinical
studies in GBM with EGFR-… study does not show clinically significant activity of erlotinib …

… , multicenter, phase II double-blind, placebo controlled trial (NCT00554775). … II study, 28
NSCLC patients harboring EGFR mutations were treated with either gefitinib or erlotinib alone ( …

… Methods: This Phase III, double-blind, randomized study (FLAURA, NCT02296125) is …
standard of care (SoC) EGFR-TKI (gefitinib [250 mg qd, orally] or erlotinib [150 mg qd, orally]) in …